Companies Announce Topline Results from Interim Analysis of Phase III BALANCE Clinical Trial Protalix management to host conference call and live webcast today at 8:30 am EDT CARMIEL, Israel and BOSTON , June 2, 2021 /PRNewswire/ -- Protalix BioTherapeutics, Inc.
Management to host conference call and live webcast today at 8:30 am EDT CARMIEL, Israel , May 14, 2021 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant
Company to host conference call and webcast at 8:30 a.m. EDT CARMIEL, Israel , May 7, 2021 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins
CARMIEL, Israel , April 28, 2021 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE:PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx ® plant cell-based
CARMIEL, Israel and BOSTON , April 28, 2021 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx ® plant
In February 2021, announced positive top-line results from the Company's phase III BRIGHT clinical trial In December 2020, announced positive final results from the Company's phase III BRIDGE clinical trial Successfully raised approximately $40 million in gross proceeds in an equity offering led by
Company to host conference call and webcast at 8:30 a.m. EDT CARMIEL, Israel , March 22, 2021 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins
CARMIEL, Israel , March 4, 2021 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx ® plant cell–based
Study achieved key objectives for safety, efficacy and pharmacokinetics After completion of the study, all patients enrolled in an extension study pegunigalsidase alfa (PRX-102) provided coverage to patients for the entire 4-week period in treated patients No new patients developed
Anticipated PDUFA for PRX-102 in Fabry disease currently set for April 27, 2021 Company, with its Commercialization Partner, Chiesi, poised to commercialize PRX-102 Additional data and milestones expected throughout 2021 CARMIEL, Israel , Feb. 18, 2021 /PRNewswire/ -- Protalix BioTherapeutics,